Praxis Precision Medicines, Inc. PRAX Relutrigine — Program-specific expenses

Other product segments

Similar metrics at other companies

HGVMarketing expense — Expenses

$239M+3.9%

HGVRental expense — Expenses

$204M+4.6%

HGVSelling expense — Expenses

$181M-7.2%

HGVClub expense — Expenses

$22M+10.0%

HGVLicense fee expense — Expenses

$53M+8.2%

HGVProperty management expense — Expenses

$37M+8.8%

FAQ

What is Praxis Precision Medicines, Inc.'s relutrigine — program-specific expenses?

Praxis Precision Medicines, Inc. (PRAX) reported relutrigine — program-specific expenses of $13.98M in Q2 2026.

How has Praxis Precision Medicines, Inc.'s relutrigine — program-specific expenses changed year-over-year?

Praxis Precision Medicines, Inc.'s relutrigine — program-specific expenses increased by 33.0% year-over-year, from $10.51M to $13.98M.

What is the long-term trend for Praxis Precision Medicines, Inc.'s relutrigine — program-specific expenses?

Over 2 years (2023 to 2025), Praxis Precision Medicines, Inc.'s relutrigine — program-specific expenses has grown at a 239.1% compound annual growth rate (CAGR), from $4M to $45.95M.

What does relutrigine — program-specific expenses mean?

This metric represents the total direct costs and operating expenses specifically attributable to the development, manufacturing, and commercialization activities of the Relutrigine product candidate. It encompasses research and development outlays, clinical trial costs, and supply chain expenditures required to advance this specific therapeutic asset through its lifecycle. By isolating these costs, the company provides transparency into the capital intensity and resource allocation dedicated to this particular clinical program.